Bocconi Partnership

Developing leadership in healthcare

New management training course for Transplant Leaders. Therakos is proud to sponsor an exciting opportunity with SDA Bocconi School of Management in Milan, as part of our ongoing commitment to training and education.

View the Program

The Programme

The full course programme is composed of two modules, an Online Elite Webinar, a Hospital Management Simulation and an Executive Hub:

Module I: Leading managerial innovation in healthcare (3 days)
Module II: Access to effective and sustainable innovation (3 days)
Online Elite Webinars: Opportunities to gather insights, ideas, expectations and needs from attendees (remotely managed)
Hospital Management Simulation: a realistic exercise that effectively simulates the complexity and intensity of the evolving hospital environment (3 days)
UHIA | "Unleashing Healthcare Innovation Access" Executive Hub: building on the competencies acquired in Module II, participants will be analysing and discussing experiences and use-cases, and how innovation can be managed, given the trade-offs between evidence-based approaches and system sustainability (1 day)

Course Goals

In our ever-changing healthcare environment, it’s important to stay up-to-date – and so this course will help towards empowering you to drive sustainable and value-based innovations in the healthcare sector, whilst helping you become a thoughtful leader required in today’s healthcare organisations.

The course is also designed to help you familiarise yourself with new critical thinking strategies, as well as new approaches in assessing and selecting technologies, reimbursement schedules and procurement schemes.

Where to sign-up

We hope you will find this an innovative education experience. For further information regarding the course and how to participate, you can send an email to Annarita Esposito – annarita.esposito@mnk.com

Places are limited and subject to approval/vetting by Bocconi. Places are given on a first come, first served basis.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Bocconi Partnership

Developing leadership in healthcare

The Programme

Course Goals

Where to sign-up

Discover more

THERAKOS™ CELLEX™ Photopheresis System

THERAKOS ECP Immunomodulation™

Health Economics

Welcome to the Home of ECP

You are leaving the Therakos.eu website.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS